Important Dates

no event

Latest News

Announcement: GENERATION HD1 study results published

GENERATION HD1 – This Phase 3 trial was stopped in March 2021 following a benefit–risk assessment by an independent data monitoring committee. A letter published 07/12/2023 in the New England Journal of Medicine (DOI: 10.1056/NEJMc2300400) details ad hoc analyses conducted on the week 69 data. Findings suggest that younger participants with lower disease burden may […]


EHDN Plenary Meeting and Enroll-HD Congress Strasbourg 2024 – Save the Date!

Dear Friends of EHDN,   It is our pleasure to cordially invite you to the EHDN Plenary Meeting and Enroll-HD Congress Thursday 12th to Saturday 14th September, 2024 Strasbourg, France   The EHDN and Enroll-HD 2024 is a collaborative event combining the EHDN Plenary Meeting and the Enroll-HD Congress. The event will be held across […]


Good news from PTC and uniQure!

On 21 June 2023, positive findings from both PTC Therapeutics and uniQure were shared with the HD community on their respective huntingtin (HTT)-lowering approaches to treating HD. PTC’s interim 12-week data from the global PIVOT-HD trial of PTC518 showed dose-dependent lowering of HTT protein levels, confirmed the intended exposure in cerebrospinal fluid, and indicated a […]